Aquestive Therapeutics Inc. (NASDAQ: AQST) reported Q1 EPS of ($0.17), $0.09 worse than the analyst estimate of ($0.08). Revenue for the quarter came in at $12.05 million versus the consensus estimate of $12.46 million.

GUIDANCE:

Aquestive Therapeutics Inc. sees FY2024 revenue of $48-51 million, versus the consensus of $50.1 million.

For earnings history and earnings-related data on Aquestive Therapeutics Inc. (AQST) click here.